Supplements vergleichen

Investigational / China-only dosing: once-weekly subcutaneous injection, dose-escalated over several weeks. Trial maintenance doses studied were 4 mg, 6 mg, and 9 mg once weekly (lower doses used during titration to limit GI effects). There is no FDA-approved regimen.

Any time

Einmal wöchentliche subkutane Injektion (in Erprobung; in China als Xinermei zugelassen)

INVESTIGATIONAL — no approved consumer dose. In trials, once-daily oral orforglipron was titrated up to 36 mg (some phase-2 cohorts to 45 mg) with gradual dose escalation to limit GI side effects. Not for self-administration; only appropriate within a clinical trial or, if/when approved, under a prescribing clinician.

Any time

Orale Tablette (experimentell)

• Pregnancy and breastfeeding
• Personal or family history of medullary thyroid carcinoma or MEN2 (class-level precaution for GLP-1-based agents)
• History of pancreatitis (use with caution / avoid)

• Insulin and sulfonylureas
• Oral medications generally

• Not an approved medicine — only appropriate within a clinical trial or, if/when approved, under a clinician
• Expected: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — the GLP-1-class thyroid C-cell concern
• History of pancreatitis (caution, consistent with the GLP-1 class)

• Insulin and sulfonylureas
• Oral medications (general)
• Other GLP-1 receptor agonists